Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-Current Assets (2016 - 2026)

Ironwood Pharmaceuticals' Non-Current Assets history spans 16 years, with the latest figure at $122.7 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 27.18% to $122.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $562.8 million, a 31.99% decrease, with the full-year FY2025 number at $122.7 million, down 27.18% from a year prior.
  • Non-Current Assets hit $122.7 million in Q4 2025 for Ironwood Pharmaceuticals, roughly flat from $122.2 million in the prior quarter.
  • Over the last five years, Non-Current Assets for IRWD hit a ceiling of $387.0 million in Q2 2021 and a floor of $61.1 million in Q1 2021.
  • Historically, Non-Current Assets has averaged $254.0 million across 5 years, with a median of $254.1 million in 2023.
  • Biggest five-year swings in Non-Current Assets: soared 550.77% in 2021 and later tumbled 42.05% in 2025.
  • Tracing IRWD's Non-Current Assets over 5 years: stood at $381.7 million in 2021, then fell by 16.19% to $319.9 million in 2022, then decreased by 25.67% to $237.8 million in 2023, then decreased by 29.12% to $168.5 million in 2024, then decreased by 27.18% to $122.7 million in 2025.
  • Business Quant data shows Non-Current Assets for IRWD at $122.7 million in Q4 2025, $122.2 million in Q3 2025, and $151.2 million in Q2 2025.